Abstract A049: Impact of Actionable Genomic Alterations (AGA) on the Efficacy of Durvalumab in Patients with Locally Advanced NSCLC Treated with Concurrent Chemoradiotherapy
Year: 2025
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4415444397
Cites:
Cited by:
Related to: